Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Invest New Drugs
Главные авторы: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2015
Предметы:
Phase II Studies
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4608248/
https://ncbi.nlm.nih.gov/pubmed/26123926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0269-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы